Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process

• Published in: Vaccine Vol. 42; no. 4; pp. 987 - 994
• Main Authors: Okumoto, Atsuko, Nomura, Yumiko, Okuda, Shin, Shikano, Mayumi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 06.02.2024; Elsevier Limited
• Subjects: Chicken pox; Clinical trials; Committees; Data collection; Decision making; Disease control; Effectiveness; Epidemiology; FDA approval; Hepatitis B; Herpes viruses; Immunization; Immunization Program; Infectious disease; Infectious diseases; Intestinal obstruction; Japan; Public health; Risk assessment; Rotavirus; Safety; Schedules; Side effects; Surveillance; Vaccines; United States > US; Japan; Hib; FDA; MHLW; PCV; CDC; Japan; Immunization Program; Vaccines; Epidemiology; HPV; Infectious disease; Surveillance; ACIP; DTaP-IPV; GVAP; MMWR; WHO
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2023.12.058

Routine vaccinations help prevent the outbreak and spread of infectious diseases; however, it can take up to ten years from vaccine approval to introduction into routine vaccination schedules in Japan. Here, we investigate the information required to introduce an approved vaccine into routine vaccination schedules and the reasons why it takes so long. Based on the published data of the Immunization and Vaccine Committee of the Health Science Council, we set out to explore ways to facilitate discussion on this topic. The following issues were identified as discussion points: disease burden, efficacy and safety, and cost-effectiveness. Until now, epidemiological information has been used to evaluate the efficacy of vaccines, and also to evaluate the safety in the presence of notable adverse reactions. However, in some cases, it took a long time to obtain epidemiological information regarding the frequency of rare but serious adverse reactions and the need for a booster dose. Given the risk of spreading infectious diseases due to delays in decision-making, vaccines may have to be introduced into routine vaccination schedules based on the results of clinical trials that can be obtained in a relatively short period. In contrast, epidemiological information is necessary to evaluate the disease burden, frequency of adverse reactions, and the necessity of booster doses. Therefore, developing an epidemiological information collection system is urgently required.